Pharmaceutical giant AstraZeneca has paused a significant £200 million investment in its Cambridge research site, a move that casts a shadow over the UK’s life sciences sector. The decision, which was expected to create 1,000 jobs, follows a pattern of major pharmaceutical companies reassessing their UK commitments due to concerns about government investment and policy.
Key Takeaways
- AstraZeneca’s £200m Cambridge investment pause is the latest blow to the UK’s pharmaceutical industry.
- The move comes after Merck scrapped a £1bn UK expansion and amid US pressure on firms to invest domestically.
- Industry executives cite falling UK spending on medicines and uncompetitive pricing thresholds as major deterrents.
Investment Freeze Signals Broader Industry Concerns
AstraZeneca’s decision to pause its Cambridge expansion, announced on Friday, marks a significant setback for the UK’s ambition to be a global leader in life sciences. This follows the shelving of another project in Liverpool earlier this year. The company stated, "We constantly reassess the investment needs of our company and can confirm our expansion in Cambridge is paused." This pause means that none of the £650 million in UK investment previously announced by the government is currently proceeding.
Economic and Policy Headwinds
The pharmaceutical industry is facing a challenging environment in the UK. Spending on medicines as a percentage of the NHS budget has fallen to 9% over the last decade, significantly lower than the 14-20% seen in other developed nations. Furthermore, US President Donald Trump’s administration has been actively encouraging pharmaceutical firms to increase investment in the United States, with AstraZeneca itself announcing a $50 billion investment in US manufacturing and R&D in July.
Industry Voices Raise Alarm
Senior figures within the pharmaceutical sector have voiced strong concerns about the UK’s attractiveness for investment. Paul Naish, UK head of market access for Sanofi, described Britain as "a terrible place to sell medicines" and "not a good place to do the development work for medicines," citing high operating costs and a lack of a clear government roadmap for increasing spending on new drugs. He highlighted that Sanofi has reduced its clinical trials in the UK by 50% in the past two years.
Similarly, MSD (known as Merck in the US) recently abandoned its £1 billion research centre in London, attributing the decision to successive governments undervaluing innovative medicines. Eli Lilly has also put its planned London gateway lab on hold, awaiting improvements in the commercial environment.
Calls for Policy Reform
Industry bodies are urging the government to update pricing thresholds set by the National Institute for Health and Care Excellence (NICE), which have remained unchanged since 1999. They also advocate for a reduction in the clawback rate, where drugmakers repay a significant portion of their UK revenues to the NHS, to levels comparable with other European countries. While government officials are reportedly attempting to re-engage with pharmaceutical companies on drug pricing, the current climate suggests a significant shift in policy may be needed to reverse the trend of declining investment.
